Drugs / DCVC H1 HA mRNA vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05945485 | Oct 2023 → May 2026 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCVC H1 HA mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05945485 ↗ |
| Modality | Messenger RNA (mRNA) | “A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA” NCT05945485 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05945485 ↗ |